Quintiles opens research centre in Hyderabad, India

Further expands global Phase I service

US biopharmaceutical services firm Quintiles has opened a new Phase I research facility in Hyderabad, India at Apollo Health City.

Built in partnership with Apollo Hospitals Group, an integrated healthcare company with more than 8,500 beds across 50 hospitals and in excess of 1,200 pharmacies and 100 diagnostic clinics across India, the facility will complement Quintiles’ other Phase I facilities located in the UK, Sweden and the US.

Eddie Caffrey, senior vp and head of Quintiles Phase I globally, said: ‘With this new, state-of-the-art, Phase I facility we will be better able to ally with customers by providing access to large numbers of healthy volunteers for simple studies, in parallel to more complex studies conducted by scientific experts in Europe and the US.’

Apollo Hospitals Group executive director Shobana Kamineni added: ‘Apollo has pioneered the provision of many medical and surgical procedures in India and our mission is to bring healthcare of international standards to within the reach of every individual.

‘With this new unit we are reinforcing India’s position as a key player in the global drug development market and expanding the options available to pharma sponsors.’

The team in Hyderabad, led by executive director Ashish Jain, will work to global standards and procedures and will be linked electronically to sites in London, Uppsala and Kansas, simplifying study management and providing integrated information as early as possible in the development process.

The 86-bed unit will evaluate compounds developed in India and elsewhere. Thirty-two beds are equipped with diagnostic cardiology equipment for TQT studies.

In addition to the Apollo Health City facility in Hyderabad, Quintiles has operations in Ahmedabad, Bangalore, Delhi, and Mumbai covering a number of therapeutic areas, including oncology, CNS, infectious disease and cardiovascular disease.

Companies